“LORLATINIB IN CRISOTINIB-RESISTANT ALK+ NSCLC PATIENTS. OUR RESULT”. 2019. Voprosy Onkologii 65 (3): 386-92. https://doi.org/10.37469/0507-3758-2019-65-3-386-392.